JP2023025005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023025005A5 JP2023025005A5 JP2022178566A JP2022178566A JP2023025005A5 JP 2023025005 A5 JP2023025005 A5 JP 2023025005A5 JP 2022178566 A JP2022178566 A JP 2022178566A JP 2022178566 A JP2022178566 A JP 2022178566A JP 2023025005 A5 JP2023025005 A5 JP 2023025005A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- virus
- vectors
- phage
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 claims description 35
- 239000013603 viral vector Substances 0.000 claims description 5
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 241000701959 Escherichia virus Lambda Species 0.000 claims 1
- 241000724791 Filamentous phage Species 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025092726A JP2025143268A (ja) | 2013-01-17 | 2025-06-03 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13151593 | 2013-01-17 | ||
| EP13151593.4 | 2013-01-17 | ||
| JP2020135954A JP7685737B2 (ja) | 2013-01-17 | 2020-08-11 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020135954A Division JP7685737B2 (ja) | 2013-01-17 | 2020-08-11 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025092726A Division JP2025143268A (ja) | 2013-01-17 | 2025-06-03 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023025005A JP2023025005A (ja) | 2023-02-21 |
| JP2023025005A5 true JP2023025005A5 (enExample) | 2024-10-31 |
Family
ID=47559322
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553072A Active JP6809789B2 (ja) | 2013-01-17 | 2014-01-16 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2020135954A Active JP7685737B2 (ja) | 2013-01-17 | 2020-08-11 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2022178566A Pending JP2023025005A (ja) | 2013-01-17 | 2022-11-08 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2025092726A Pending JP2025143268A (ja) | 2013-01-17 | 2025-06-03 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553072A Active JP6809789B2 (ja) | 2013-01-17 | 2014-01-16 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2020135954A Active JP7685737B2 (ja) | 2013-01-17 | 2020-08-11 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025092726A Pending JP2025143268A (ja) | 2013-01-17 | 2025-06-03 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10369198B2 (enExample) |
| EP (2) | EP3747457A3 (enExample) |
| JP (4) | JP6809789B2 (enExample) |
| CN (6) | CN110903378A (enExample) |
| CA (1) | CA2898128A1 (enExample) |
| DK (1) | DK2945642T3 (enExample) |
| ES (1) | ES2986021T3 (enExample) |
| FI (1) | FI2945642T3 (enExample) |
| HR (1) | HRP20240623T1 (enExample) |
| HU (1) | HUE068364T2 (enExample) |
| LT (1) | LT2945642T (enExample) |
| PL (1) | PL2945642T3 (enExample) |
| PT (1) | PT2945642T (enExample) |
| RS (1) | RS65553B1 (enExample) |
| SI (1) | SI2945642T1 (enExample) |
| WO (1) | WO2014111458A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014111458A2 (en) * | 2013-01-17 | 2014-07-24 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
| EP4005585B1 (en) | 2013-11-21 | 2024-03-27 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating right ventricular hypertrophy |
| CA2956256A1 (en) * | 2014-08-01 | 2016-02-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| US10435757B1 (en) | 2016-06-15 | 2019-10-08 | University Of South Florida | Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof |
| CN108802372B (zh) * | 2018-06-19 | 2021-05-11 | 上海伦泽生物科技有限公司 | 检测人血清中内质网膜蛋白复合体亚单位10的试剂盒 |
| CN115698048A (zh) | 2020-01-21 | 2023-02-03 | 勃林格殷格翰国际有限公司 | 用于治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子 |
| CN114149500B (zh) * | 2020-09-07 | 2023-12-01 | 复旦大学附属华山医院 | 抗人emc10的单克隆抗体在制备治疗和/或预防脂肪肝的产品中的应用 |
| CN114149498B (zh) * | 2020-09-07 | 2023-12-05 | 复旦大学附属华山医院 | 抗人emc10的单克隆抗体在防治2型糖尿病中的应用 |
| CN114149499B (zh) * | 2020-09-07 | 2023-12-05 | 复旦大学附属华山医院 | 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用 |
| EP4267594A1 (en) | 2020-12-23 | 2023-11-01 | Boehringer Ingelheim International GmbH | Viral capsid proteins with specificity to heart tissue cells |
| AU2022307365A1 (en) * | 2021-07-08 | 2024-02-01 | Tenaya Therapeutics, Inc. | Optimized expression cassettes for gene therapy |
| KR20250031229A (ko) | 2022-06-03 | 2025-03-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 골수 유래된 성장 인자의 재조합 발현 |
| WO2024052563A1 (en) | 2022-09-08 | 2024-03-14 | Boehringer Ingelheim International Gmbh | Myeloid-derived growth factor for use in treating cardiogenic shock |
| TW202528339A (zh) | 2023-09-01 | 2025-07-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療或預防肝臟病症之骨髓源性生長因子 |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| US20250186549A1 (en) | 2023-12-06 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Novel formulation comprising myeloid-derived growth factor |
| CN120738287A (zh) * | 2025-07-03 | 2025-10-03 | 广州医科大学附属妇女儿童医疗中心 | 急性低灌注动物模型的构建方法及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| JP2002500502A (ja) | 1996-06-11 | 2002-01-08 | メルク エンド カンパニー インコーポレーテッド | 合成ｃ型肝炎遺伝子 |
| JP2001506484A (ja) * | 1996-09-13 | 2001-05-22 | 財団法人相模中央化学研究所 | 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ |
| CA2265923A1 (en) * | 1996-09-13 | 1998-03-19 | Sagami Chemical Research Center | Human proteins having secretory signal sequences and dnas encoding these proteins |
| WO2002008284A2 (en) * | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2000073445A2 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Interleukin-1-receptor associated kinase-3 (irak3) |
| PL334902A1 (en) * | 1997-01-29 | 2000-03-27 | Cornell Res Foundation Inc | Repeatable local delivery of adenoviral vector in order to induce angiogenesis |
| DE60045243D1 (de) | 1999-05-26 | 2010-12-30 | Next Biomed Technologies Nbt Oy | VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN |
| WO2001012669A1 (en) * | 1999-08-16 | 2001-02-22 | Universita' Degli Studi Di Siena | Vegf-d and angiogenic use thereof |
| WO2002081681A1 (fr) * | 2001-03-30 | 2002-10-17 | Chugai Seiyaku Kabushiki Kaisha | Nouvelle utilisation de la cytokine sf20 |
| DE10119804A1 (de) * | 2001-04-23 | 2002-10-24 | Brahms Ag | Entzündungsspezifische Peptide und deren Verwendungen |
| WO2004060867A2 (en) | 2003-01-02 | 2004-07-22 | Timothy Kirk Gallaher | Secreted protein factor and cell membrane-bound splice variant |
| WO2004069173A2 (en) * | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US8486438B2 (en) | 2004-01-29 | 2013-07-16 | Brown University | Methods for progenitor cell recruitment and isolation |
| CN101160055A (zh) * | 2005-02-16 | 2008-04-09 | 莱蒂恩公司 | 慢病毒载体及其用途 |
| US20080004232A1 (en) * | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| EP2130547A1 (en) * | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| PE20121647A1 (es) * | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| US8735342B2 (en) | 2010-01-27 | 2014-05-27 | Neumedicines, Inc. | Method for treating brain cancer using a novel tumor suppressor gene and secreted factor |
| KR20120095063A (ko) * | 2011-02-18 | 2012-08-28 | 가톨릭대학교 산학협력단 | ＩＬ-27로 유도된 ｐ53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
| WO2014111458A2 (en) * | 2013-01-17 | 2014-07-24 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
-
2014
- 2014-01-16 WO PCT/EP2014/050788 patent/WO2014111458A2/en not_active Ceased
- 2014-01-16 LT LTEPPCT/EP2014/050788T patent/LT2945642T/lt unknown
- 2014-01-16 SI SI201432073T patent/SI2945642T1/sl unknown
- 2014-01-16 PT PT147008726T patent/PT2945642T/pt unknown
- 2014-01-16 CN CN201911137855.8A patent/CN110903378A/zh active Pending
- 2014-01-16 US US14/759,852 patent/US10369198B2/en active Active
- 2014-01-16 ES ES14700872T patent/ES2986021T3/es active Active
- 2014-01-16 CA CA2898128A patent/CA2898128A1/en active Pending
- 2014-01-16 CN CN201911124174.8A patent/CN110894226A/zh active Pending
- 2014-01-16 DK DK14700872.6T patent/DK2945642T3/da active
- 2014-01-16 CN CN201911137854.3A patent/CN110922468B/zh active Active
- 2014-01-16 CN CN201911137853.9A patent/CN111100197B/zh active Active
- 2014-01-16 JP JP2015553072A patent/JP6809789B2/ja active Active
- 2014-01-16 EP EP20178045.9A patent/EP3747457A3/en active Pending
- 2014-01-16 FI FIEP14700872.6T patent/FI2945642T3/fi active
- 2014-01-16 HR HRP20240623TT patent/HRP20240623T1/hr unknown
- 2014-01-16 CN CN201480005079.5A patent/CN104968361B/zh active Active
- 2014-01-16 HU HUE14700872A patent/HUE068364T2/hu unknown
- 2014-01-16 CN CN201911138039.9A patent/CN110922467A/zh active Pending
- 2014-01-16 PL PL14700872.6T patent/PL2945642T3/pl unknown
- 2014-01-16 EP EP14700872.6A patent/EP2945642B1/en active Active
- 2014-01-16 RS RS20240548A patent/RS65553B1/sr unknown
-
2020
- 2020-08-11 JP JP2020135954A patent/JP7685737B2/ja active Active
-
2022
- 2022-11-08 JP JP2022178566A patent/JP2023025005A/ja active Pending
-
2025
- 2025-06-03 JP JP2025092726A patent/JP2025143268A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023025005A5 (enExample) | ||
| JP2020203894A5 (enExample) | ||
| JP2022051775A5 (enExample) | ||
| JP2020505025A5 (enExample) | ||
| Girones et al. | Mutation rate of the hepadnavirus genome | |
| JP2009525757A5 (enExample) | ||
| JP2019504868A5 (enExample) | ||
| JP2022160401A5 (enExample) | ||
| JP2017518372A5 (enExample) | ||
| JP2022066336A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| JP2005502355A5 (enExample) | ||
| JP2020531032A5 (enExample) | ||
| JP2020517635A5 (enExample) | ||
| MX2020003176A (es) | Variantes de capsides de virus adenoasociados y metodos de uso de estas. | |
| JP2018520997A5 (enExample) | ||
| JP2016506416A5 (enExample) | ||
| WO2003047617A3 (en) | Vaccine | |
| JP2017521074A5 (enExample) | ||
| JP2019214579A5 (enExample) | ||
| JP2020534284A5 (enExample) | ||
| JP2004524805A5 (enExample) | ||
| JP2006511212A5 (enExample) | ||
| Khatri et al. | Gene Expression by Atypical Recombinant Ovine Adenovirus Vectors during Abortive Infection of Human and Animal Cellsin Vitro | |
| JP2690813B2 (ja) | 修飾タンパク質およびそれを用いたウイルス感染症を制御するための医薬製剤 |